Patten Group Inc. lessened its stake in shares of Zoetis Inc (NYSE:ZTS) by 95.9% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 73 shares of the company’s stock after selling 1,727 shares during the period. Patten Group Inc.’s holdings in Zoetis were worth $115,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Wilbanks Smith & Thomas Asset Management LLC boosted its holdings in shares of Zoetis by 1.8% during the 2nd quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 5,682 shares of the company’s stock valued at $354,000 after purchasing an additional 98 shares during the last quarter. Scotia Capital Inc. lifted its holdings in shares of Zoetis by 1.5% in the 2nd quarter. Scotia Capital Inc. now owns 9,628 shares of the company’s stock valued at $601,000 after acquiring an additional 142 shares during the last quarter. Nordea Investment Management AB lifted its holdings in shares of Zoetis by 0.7% in the 2nd quarter. Nordea Investment Management AB now owns 24,854 shares of the company’s stock valued at $1,550,000 after acquiring an additional 169 shares during the last quarter. Moors & Cabot Inc. lifted its holdings in shares of Zoetis by 1.1% in the 2nd quarter. Moors & Cabot Inc. now owns 14,969 shares of the company’s stock valued at $929,000 after acquiring an additional 170 shares during the last quarter. Finally, Bronfman E.L. Rothschild L.P. lifted its holdings in shares of Zoetis by 8.5% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 2,789 shares of the company’s stock valued at $174,000 after acquiring an additional 219 shares during the last quarter. 93.33% of the stock is owned by institutional investors and hedge funds.

Shares of Zoetis Inc (ZTS) traded up $0.15 during midday trading on Thursday, reaching $72.38. 1,595,000 shares of the company’s stock traded hands, compared to its average volume of 2,752,414. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45. The company has a market capitalization of $35,270.00, a P/E ratio of 33.13, a P/E/G ratio of 2.17 and a beta of 1.06. Zoetis Inc has a twelve month low of $50.57 and a twelve month high of $72.99.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.02. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The firm’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.52 earnings per share. research analysts predict that Zoetis Inc will post 2.37 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, January 19th will be paid a $0.126 dividend. The ex-dividend date of this dividend is Thursday, January 18th. This represents a $0.50 annualized dividend and a yield of 0.70%. This is an increase from Zoetis’s previous quarterly dividend of $0.11. Zoetis’s dividend payout ratio (DPR) is presently 22.11%.

A number of research analysts recently commented on the stock. Cantor Fitzgerald set a $80.00 price target on shares of Zoetis and gave the company a “buy” rating in a report on Tuesday. Morgan Stanley raised shares of Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 price target for the company in a report on Wednesday, November 29th. UBS reaffirmed a “neutral” rating on shares of Zoetis in a report on Friday, November 24th. Cowen set a $80.00 price target on shares of Zoetis and gave the company a “buy” rating in a report on Friday, November 17th. Finally, Jefferies Group reaffirmed a “buy” rating on shares of Zoetis in a report on Friday, November 10th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have assigned a buy rating to the company. Zoetis has a consensus rating of “Buy” and a consensus target price of $68.53.

TRADEMARK VIOLATION NOTICE: This report was posted by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.watchlistnews.com/patten-group-inc-reduces-holdings-in-zoetis-inc-zts/1764127.html.

Zoetis Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with Analyst Ratings Network's FREE daily email newsletter.